Rapid identification and antimicrobial-drug resistance of nontuberculous mycobacteria from
post-operative chronic non-healing wound patients at tertiary care centre in northern India
A.K. Singh*, T.N. Dhole, A.K. Maurya, R.S.K. Marak, A.K. Singh, M. Kumar, J. Umrao, R. Singh, R.
Garg, S. Kant (Lucknow, IN)
Objectives: Mycobacterium tuberculosis complex and nontuberculous mycobacteria (NTM) may or
may not have same clinical presentations, but the treatment regimens are always different. Previous
few reports suggest that the prevalence of NTM has increased particularly in post-operative patients,
but population-based data to substantiate this are still lacking. The present study aimed to evaluate
the clinical utility of the novel GenoType® Mycobacterium Common Mycobacterial/Additional Species
(CM/AS) assay for rapid identification of NTM, their risk factors and antimicrobial drug resistance
among clinical isolates of chronic non-healing wound cases at a tertiary care hospital in Northern
Methods: We conducted a prospective clinico-microbiological analysis of all the patients of having
chronic nonhealing post-operative wound infections from January 2009-October 2012. Discharging
pus/drains were processed for Ziehl-Neelsen staining, culture by BacT/ALERT® MP and simultaneous
identification from clinical specimens by GenoType® CM/AS assay (Hain Lifescience, Nehren,
Germany). Antimicrobial sensitivity testing was performed only for rapidly growing mycobacteria
(RGM) by broth microdilution method using CLSI guideline.
Results: We identified 208 patients who presented or referred to our centre with chronic non healing
wound with suspected NTM infection. Among these a total of 41 (19.7%) NTMs were isolated; and
identified as Mycobacterium fortuitum (36.6%) the most common species followed by M. ulcerans
(14.6%). These types of infection caused by NTMs was significantly higher in patients who had
operated with laparoscope (80.5%) and in age group >20-40 years (63.4%) [p<0.05]. Resistance to
doxycycline (39.3%), cefoxitin (25.0%), linezolid (21.4%), ciprofloxacin (21.4%), co-trimoxazole
(17.9%), clarithromycin (17.9%), ceftriaxone (14.3%), amikacin (10.7%) and imipenem (7.1%) were
higher among 28/41 (68.3%) RGM tested.
Conclusion: We found NTM was frequently isolated (19.7%) from post-operative chronic non-healing
wound cases and represented a true infection. The most common species and risk factor associated
with NTM was M. fortuitum (36.6%) and use of laparoscope during surgeries respectively (80.5%;
p<0.05). The most common resistance was seen with doxycycline (39.3%) and cefoxitin (25.0%)
among RGM. The GenoType® assay makes rapid and accurate identification of NTM even directly
from clinical specimens for the definitive management of these NTM infections.
HOLY WATER Regia : Tom Reeve - Sceneggiatura : Michael O'Mahony - Fotografia : Joost van Starrenburg - Musica : Tom Batoy, Franco Tortora - Interpreti : John Lynch, Cornelius Clarke, Lochlann O'Mearan, Cian Barry, Susan Lynch, Linda Hamilton, Deirdre Mullins, Tommy 'Tiny' Lister, Stanley Townsend, Angeline Ball, Ray Cal aghan, Frank Dunne, Adam Astill, Lisa Catara, Dara Clear, Chrissi
Bristol-Myers Squibb Announces Restatement, Reports 2002 Full-Year Results and Reiterates Earnings Guidance for 2003 • Restatement: § Primarily to correct accounting for U.S. pharmaceuticals sales to two wholesalers by reallocating approximately $2 billion of net sales and $1.5 billion in pre-tax earnings from 1999 through 2001 to 2002 and 2003 § Additional restatement adjustmen